FISH and chips: The recipe for improved prognostication and outcomes for children with medulloblastoma

Cancer Genetics

Volumn 204, Issue 11, 2011, Pages 577-588

  Ramaswamy, Vijay ^a   Northcott, Paul A ^a   Taylor, Michael D ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Copy number alterations; Genomics; Medulloblastoma; Prognosis; Subgroups

Indexed keywords

BETA CATENIN; ERISMODEGIB; MICRORNA; OLIGONUCLEOTIDE; VISMODEGIB;

CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; EPIGENETICS; FAMILIAL DISEASE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; GENETIC VARIABILITY; HISTOLOGY; HUMAN; KARYOTYPING; MEDULLOBLASTOMA; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; ONCOGENE MYC; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; CEREBELLUM TUMOR; CHILD; DNA MICROARRAY; GENETICS; METHODOLOGY; MORTALITY; ONCOGENE; PROGNOSIS;

ERINACEIDAE;

CEREBELLAR NEOPLASMS; CHILD; CHROMOSOME ABERRATIONS; COMPARATIVE GENOMIC HYBRIDIZATION; EPIGENOMICS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; MEDULLOBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENES; PROGNOSIS;

EID: 84857091284     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2011.11.001     Document Type: Review

References (132)

1. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2007 2011, CBTRUS, Central Brain Tumor Registry of the United States, Hinsdale, IL.
2. Packer R.J., Rood B.R., MacDonald T.J. Medulloblastoma: present concepts of stratification into risk groups. Pediatr Neurosurg 2003, 39:60-67.
3. Eberhart C.G., Kratz J., Wang Y., et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 2004, 63:441-449.
4. Gajjar A. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 2004, 22:984-993.
5. Packer R.J., Gajjar A., Vezina G., et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006, 24:4202-4208.
6. Polkinghorn W.R., Dunkel I.J., Souweidane M.M., et al. Disease control and ototoxicity using intensity-modulated radiation therapy tumor-bed boost for medulloblastoma. Int J Radiat Oncol Biol Phys 2011, 81:e15-e20.
7. Crawford J.R., MacDonald T.J., Packer R.J. Medulloblastoma in childhood: new biological advances. Lancet Neurol 2007, 6:1073-1085.
8. Gajjar A., Chintagumpala M., Ashley D., et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 2006, 7:813-820.
9. Grill J., Sainte-Rose C., Jouvet A., et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol 2005, 6:573-580.
10. Rutkowski S., Bode U., Deinlein F., et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005, 352:978-986.
11. Mason W.P., Grovas A., Halpern S., et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 1998, 16:210-221.
12. Rutkowski S., Cohen B., Finlay J., et al. Medulloblastoma in young children. Pediatr Blood Cancer 2010, 54:635-637.
13. von Bueren A.O., von Hoff K., Pietsch T., et al. Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. Neuro Oncol 2011, 13:669-679.
14. Packer R.J., Vezina G. Management of and prognosis with medulloblastoma: therapy at a crossroads. Arch Neurol 2008, 65:1419-1424.
15. Mulhern R.K., Merchant T.E., Gajjar A., et al. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 2004, 5:399-408.
16. Louis D.N., Ohgaki H., Wiestler O.D., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97-109.
17. Ellison D.W., Kocak M., Dalton J., et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 2011, 29:1400-1407.
18. Pietsch T., Taylor M.D., Rutka J.T. Molecular pathogenesis of childhood brain tumors. J Neurooncol 2004, 70:203-215.
19. Ellison D. Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathol Appl Neurobiol 2002, 28:257-282.
20. Abacioglu U., Uzel O., Sengoz M., et al. Medulloblastoma in adults: treatment results and prognostic factors. Int J Radiat Oncol Biol Phys 2002, 54:855-860.
21. Swedow S., Campo E., Harris N., et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC Press, Lyon.
22. Remke M., Hielscher T., Korshunov A., et al. FSTL5 is a marker of poor prognosis in non-WNT/Non-SHH medulloblastoma. J Clin Oncol 2011, 29:3852-3861.
23. Northcott P.A., Korshunov A., Witt H., et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011, 29:1408-1414.
24. Northcott P.A., Rutka J.T., Taylor M.D. Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years. Neurosurg Focus 2010, 28:E6.
25. Thompson M.C., Fuller C., Hogg T.L., et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006, 24:1924-1931.
26. Ng D., Stavrou T., Liu L., et al. Retrospective family study of childhood medulloblastoma. Am J Med Genet A 2005, 134:399-403.
27. Yokota N., Mainprize T.G., Taylor M.D., et al. Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization. Oncogene 2004, 23:3444-3453.
28. Park P.C., Taylor M.D., Mainprize T.G., et al. Transcriptional profiling of medulloblastoma in children. J Neurosurg 2003, 99:534-541.
29. Taylor M.D., Mainprize T.G., Rutka J.T. Molecular insight into medulloblastoma and central nervous system primitive neuroectodermal tumor biology from hereditary syndromes: a review. Neurosurgery 2000, 47:888-901.
30. Tamber M.S., Bansal K., Liang M.L., et al. Current concepts in the molecular genetics of pediatric brain tumors: implications for emerging therapies. Childs Nerv Syst 2006, 22:1379-1394.
31. Pfister S.M., Korshunov A., Kool M., et al. Molecular diagnostics of CNS embryonal tumors. Acta Neuropathol 2010, 120:553-566.
32. Dubuc A.M., Northcott P.A., Mack S., et al. The genetics of pediatric brain tumors. Curr Neurol Neurosci Rep 2010, 10:215-223.
33. Lubs H.A., Salmon J.H. The chromosomal complement of human solid tumors. II. Karyotypes of glial tumors. J Neurosurg 1965, 22:160-168.
34. Cox D., Yuncken C., Spriggs A.I. Minute chromatin bodies in malignant tumours of childhood. Lancet 1965, 1:55-58.
35. Friedman H.S., Bigner S.H., McComb R.D., et al. A model for human medulloblastoma. Growth, morphology, and chromosomal analysis in vitro and in athymic mice. J Neuropathol Exp Neurol 1983, 42:485-503.
36. McAllister R.M., Isaacs H., Rongey R., et al. Establishment of a human medulloblastoma cell line. Int J Cancer 1977, 20:206-212.
37. Jacobsen P.F., Jenkyn D.J., Papadimitriou J.M. Establishment of a human medulloblastoma cell line and its heterotransplantation into nude mice. J Neuropathol Exp Neurol 1985, 44:472-485.
38. Latimer F.R., AlSaadi A.A., Robbins T.O. Cytogenetic studies of human brain tumors and their clinical significance. 1. Medulloblastoma. J Neurooncol 1987, 4:287-291.
39. Griffin C.A., Hawkins A.L., Packer R.J., et al. Chromosome abnormalities in pediatric brain tumors. Cancer Res 1988, 48:175-180.
40. Bigner S.H., Mark J., Friedman H.S., et al. Structural chromosomal abnormalities in human medulloblastoma. Cancer Genet Cytogenet 1988, 30:91-101.
41. Cogen P.H., Daneshvar L., Metzger A.K., et al. Deletion mapping of the medulloblastoma locus on chromosome 17p. Genomics 1990, 8:279-285.
42. Cogen P.H., Daneshvar L., Metzger A.K., et al. Involvement of multiple chromosome 17p loci in medulloblastoma tumorigenesis: prognostic significance of molecular genetic markers in childhood brain tumors: deletion mapping of the medulloblastoma locus on chromosome 17p. Am J Hum Genet 1992, 50:584-589.
43. Thomas G.A., Raffel C. Loss of heterozygosity on 6q, 16q, and 17p in human central nervous system primitive neuroectodermal tumors. Cancer Res 1991, 51:639-643.
44. Bayani J., Zielenska M., Marrano P., et al. Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors with conventional banding, comparative genomic hybridization, and spectral karyotyping. J Neurosurg 2000, 93:437-448.
45. Emadian S.M., McDonald J.D., Gerken S.C., et al. Correlation of chromosome 17p loss with clinical outcome in medulloblastoma. Clin Cancer Res 1996, 2:1559-1564.
46. Biegel J.A., Janss A.J., Raffel C., et al. Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumors (medulloblastomas) of the central nervous system. Clin Cancer Res 1997, 3:473-478.
47. McCabe M.G., Backlund L.M., Leong H.S., et al. Chromosome 17 alterations identify good-risk and poor-risk tumors independently of clinical factors in medulloblastoma. Neuro Oncol 2011, 13:376-383.
48. Pan E., Pellarin M., Holmes E., et al. Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res 2005, 11:4733-4740.
49. Pfaff E., Remke M., Sturm D., et al. TP53 mutation is frequently associated with ctnnb1 mutation or mycn amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol 2010, 28:5188-5196.
50. Tabori U., Baskin B., Shago M., et al. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol 2010, 28:1345-1350.
51. Gilbertson R.J., Pearson A.D., Perry R.H., et al. Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br J Cancer 1995, 71:473-477.
52. McDonald J.D., Daneshvar L., Willert J.R., et al. Physical mapping of chromosome 17p13.3 in the region of a putative tumor suppressor gene important in medulloblastoma. Genomics 1994, 23:229-232.
53. Gilbertson R., Wickramasinghe C., Hernan R., et al. Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 2001, 85:705-712.
54. Batra S.K., McLendon R.E., Koo J.S., et al. Prognostic implications of chromosome 17p deletions in human medulloblastomas. J Neurooncol 1995, 24:39-45.
55. Friedman H.S., Burger P.C., Bigner S.H., et al. Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-myc. Am J Pathol 1988, 130:472-484.
56. Bigner S.H., Friedman H.S., Vogelstein B., et al. Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts. Cancer Res 1990, 50:2347-2350.
57. Pfister S., Remke M., Benner A., et al. Outcome prediction in pediatric medulloblastoma based on dna copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 2009, 27:1627-1636.
58. Cho Y.-J., Tsherniak A., Tamayo P., et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011, 29:1424-1430.
59. Grotzer M.A., Hogarty M.D., Janss A.J., et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 2001, 7:2425-2433.
60. Grotzer M.A., Janss A.J., Fung K., et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 2000, 18:1027-1035.
61. Grotzer M.A., Janss A.J., Phillips P.C., et al. Neurotrophin receptor TrkC predicts good clinical outcome in medulloblastoma and other primitive neuroectodermal brain tumors. Klin Padiatr 2000, 212:196-199.
62. Segal R.A., Goumnerova L.C., Kwon Y.K., et al. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci U S A 1994, 91:12867-12871.
63. Hottinger A.F., Khakoo Y. Neurooncology of familial cancer syndromes. J Child Neurol 2009, 24:1526-1535.
64. Hamilton S.R., Liu B., Parsons R.E., et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995, 332:839-847.
65. Clifford S.C., Lusher M.E., Lindsey J.C., et al. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular subgroup of medulloblastomas associated with a favorable prognosis. Cell Cycle 2006, 5:2666-2670.
66. Slade I., Murray A., Hanks S., et al. Heterogeneity of familial medulloblastoma and contribution of germline PTCH1 and SUFU mutations to sporadic medulloblastoma. Fam Cancer 2011, 10:337-342.
67. Brugieres L., Pierron G., Chompret A., et al. Incomplete penetrance of the predisposition to medulloblastoma associated with germ-line SUFU mutations. J Med Genet 2010, 47:142-144.
68. Taylor M.D., Zhang X., Liu L., et al. Failure of a medulloblastoma-derived mutant of SUFU to suppress WNT signaling. Oncogene 2004, 23:4577-4583.
69. Taylor M.D., Liu L., Raffel C., et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet 2002, 31:306-310.
70. Reardon D.A., Michalkiewicz E., Boyett J.M., et al. Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization. Cancer Res 1997, 57:4042-4047.
71. Nishizaki T., Harada K., Kubota H., et al. Genetic alterations in pediatric medulloblastomas detected by comparative genomic hybridization. Pediatric Neurosurg 1999, 31:27-32.
72. Bittner M., Meltzer P., Chen Y., et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000, 406:536-540.
73. Golub T.R., Slonim D.K., Tamayo P., et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286:531-537.
74. MacDonald T.J., Brown K.M., LaFleur B., et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001, 29:143-152.
75. Gilbertson R.J., Clifford S.C. PDGFRB is overexpressed in metastatic medulloblastoma. Nat Genet 2003, 35:197-198.
76. Chopra A., Brown K.M., Rood B.R., et al. The use of gene expression analysis to gain insights into signaling mechanisms of metastatic medulloblastoma. Pediatr Neurosurg 2003, 39:68-74.
77. Pomeroy S.L., Tamayo P., Gaasenbeek M., et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002, 415:436-442.
78. Biegel J.A., Zhou J.Y., Rorke L.B., et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 1999, 59:74-79.
79. Korshunov A., Remke M., Gessi M., et al. Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. Acta Neuropathol 2010, 120:253-260.
80. Pfister S., Remke M., Castoldi M., et al. Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes. Acta Neuropathol 2009, 117:457-464.
81. Kool M., Koster J., Bunt J., et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS ONE 2008, 3:e3088.
82. Ellison D.W., Onilude O.E., Lindsey J.C., et al. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 2005, 23:7951-7957.
83. Tamayo P., Cho Y.-J., Tsherniak A., et al. Predicting Relapse in Patients With Medulloblastoma by Integrating Evidence From Clinical and Genomic Features. J Clin Oncol 2011, 29:1415-1423.
84. Gibson P., Tong Y., Robinson G., et al. Subtypes of medulloblastoma have distinct developmental origins. Nature 2010, 468:1095-1099.
85. Ellison D.W., Dalton J., Kocak M., et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 2011, 121:381-396.
86. Smoll NR. Relative survival of childhood and adult medulloblastomas and primitive neuroectodermal tumors (PNETs). Cancer. [Epub ahead of print].
87. Padovani L., Sunyach M.P., Perol D., et al. Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults. Int J Radiat Oncol Biol Phys 2007, 68:433-440.
88. Ang C., Hauerstock D., Guiot M.C., et al. Characteristics and outcomes of medulloblastoma in adults. Pediatr Blood Cancer 2008, 51:603-607.
89. Korshunov A., Remke M., Werft W., et al. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol 2010, 28:3054-3060.
90. Remke M., Hielscher T., Northcott P.A., et al. Adult medulloblastoma comprises three major molecular variants. J Clin Oncol 2011, 29:2717-2723.
91. Northcott P.A., Hielscher T., Dubuc A., et al. Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol 2011, 122:231-240.
92. Al-Halabi H., Nantel A., Klekner A., et al. Preponderance of sonic hedgehog pathway activation characterizes adult medulloblastoma. Acta Neuropathol 2011, 121:229-239.
93. Buonamici S., Williams J., Morrissey M., et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2010, 2:51ra70.
94. LoRusso P.M., Rudin C.M., Reddy J.C., et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011, 17:2502-2511.
95. Skvara H., Kalthoff F., Meingassner J.G., et al. Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol 2011, 131:1735-1744.
96. Von Hoff D.D., LoRusso P.M., Rudin C.M., et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009, 361:1164-1172.
97. Yauch R.L., Dijkgraaf G.J., Alicke B., et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009, 326:572-574.
98. Rudin C.M., Hann C.L., Laterra J., et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009, 361:1173-1178.
99. Schreck K.C., Taylor P., Marchionni L., et al. The notch target Hes1 directly modulates Gli1 expression and hedgehog signaling: a potential mechanism of therapeutic resistance. Clin Cancer Res 2010, 16:6060-6070.
100. Northcott P.A., Nakahara Y., Wu X., et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 2009, 41:465-472.
101. Parsons D.W., Li M., Zhang X., et al. The genetic landscape of the childhood cancer medulloblastoma. Science 2011, 331:435-439.
102. Lim S.P., Neilsen P., Kumar R., et al. The application of delivery systems for DNA methyltransferase inhibitors. BioDrugs 2011, 25:227-242.
103. Miller C.P., Singh M.M., Rivera-Del Valle N., et al. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J Biomed Biotechnol 2011, 2011:514261.
104. Mummery A, Narendran A, Lee KY. Targeting epigenetics through histone deacetylase inhibitors in acute lymphoblastic leukemia. Curr Cancer Drug Targets [Epub ahead of print].
105. Rahman R., Grundy R. Histone deacetylase inhibition as an anticancer telomerase-targeting strategy. Int J Cancer 2011, 129:2765-2774.
106. Fruhwald M.C., O'Dorisio M.S., Dai Z., et al. Aberrant hypermethylation of the major breakpoint cluster region in 17p11.2 in medulloblastomas but not supratentorial PNETs. Genes Chromosomes Cancer 2001, 30:38-47.
107. Fruhwald M.C., O'Dorisio M.S., Dai Z., et al. Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas-implications for tumor biology and potential clinical utility. Oncogene 2001, 20:5033-5042.
108. Fruhwald M.C., O'Dorisio M.S., Smith L., et al. [Hypermethylation as a potential prognostic factor and a clue to a better understanding of the molecular pathogenesis of medulloblastoma-results of a genomewide methylation scan]. Klin Padiatr 2001, 213:197-203.
109. Lindsey J.C., Lusher M.E., Anderton J.A., et al. Epigenetic deregulation of multiple S100 gene family members by differential hypomethylation and hypermethylation events in medulloblastoma. Br J Cancer 2007, 97:267-274.
110. Muhlisch J., Bajanowski T., Rickert C.H., et al. Frequent but borderline methylation of p16 (INK4a) and TIMP3 in medulloblastoma and sPNET revealed by quantitative analyses. J Neurooncol 2007, 83:17-29.
111. Scott D.K., Straughton D., Cole M., et al. Identification and analysis of tumor suppressor loci at chromosome 10q23.3-10q25.3 in medulloblastoma. Cell Cycle 2006, 5:2381-2389.
112. Anderton J.A., Lindsey J.C., Lusher M.E., et al. Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2. Neuro-oncology 2008, 10:981-994.
113. Kongkham P.N., Northcott P.A., Croul S.E., et al. The SFRP family of WNT inhibitors function as novel tumor suppressor genes epigenetically silenced in medulloblastoma. Oncogene 2010, 29:3017-3024.
114. Nakahara Y., Northcott P.A., Li M., et al. Genetic and epigenetic inactivation of Kruppel-like factor 4 in medulloblastoma. Neoplasia 2010, 12:20-27.
115. Kongkham P.N., Northcott P.A., Ra Y.S., et al. An epigenetic genome-wide screen identifies spint2 as a novel tumor suppressor gene in pediatric medulloblastoma. Cancer Res 2008, 68:9945-9953.
116. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
117. Hegi M.E., Liu L., Herman J.G., et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008, 26:4189-4199.
118. Faoro D., von Bueren A.O., Shalaby T., et al. Expression of O-methylguanine-DNA methyltransferase in childhood medulloblastoma. J Neurooncol 2011, 103:59-69.
119. Garzon R., Calin G.A., Croce C.M. MicroRNAs in Cancer. Annu Rev Med 2009, 60:167-179.
120. Ajeawung N.F., Li B., Kamnasaran D. Translational applications of microRNA genes in medulloblastomas. Clin Invest Med 2010, 33:E223-E233.
121. Birks D.K., Barton V.N., Donson A.M., et al. Survey of microRNA expression in pediatric brain tumors. Pediatr Blood Cancer 2011, 56:211-216.
122. Ferretti E., De Smaele E., Miele E., et al. Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells. EMBO J 2008, 27:2616-2627.
123. Ferretti E., De Smaele E., Po A., et al. MicroRNA profiling in human medulloblastoma. Int J Cancer 2009, 124:568-577.
124. Garzia L., Andolfo I., Cusanelli E., et al. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS ONE 2009, 4:e4998.
125. Gokhale A., Kunder R., Goel A., et al. Distinctive microRNA signature of medulloblastomas associated with the WNT signaling pathway. J Cancer Res Ther 2010, 6:521-529.
126. Liu W., Gong Y.H., Chao T.F., et al. Identification of differentially expressed microRNAs by microarray: a possible role for microRNAs gene in medulloblastomas. Chin Med J (Engl) 2009, 122:2405-2411.
127. Lv SQ, Kim YH, Giulio F, et al. Genetic Alterations in Micro-RNAs in Medulloblastomas. Brain Pathol. [Epub ahead of print].
128. Northcott P.A., Fernandez L.A., Hagan J.P., et al. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res 2009, 69:3249-3255.
129. Pierson J., Hostager B., Fan R., et al. Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. J Neurooncol 2008, 90:1-7.
130. Uziel T., Karginov F.V., Xie S., et al. The miR-17∼92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc Natl Acad Sci USA 2009, 106:2812-2817.
131. Fernandez L.A., Northcott P.A., Taylor M.D., et al. Normal and oncogenic roles for microRNAs in the developing brain. Cell Cycle 2009, 8:4049-4054.
132. Consortium I.C.G. International network of cancer genome projects. Nature 2010, 464:993-998.